Neurocrine Biosciences (NBIX) Inventory (2017 - 2026)

Neurocrine Biosciences' Inventory history runs 10 years deep, the most recent figure standing at $64.5 million for Q1 2026.

• Quarterly Inventory rose 9.14% year-over-year to $64.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.5 million (up 9.14% YoY) and the FY2025 annual result came in at $69.0 million, up 20.21% from the prior year.
• Inventory was $64.5 million for Q1 2026 at Neurocrine Biosciences, down from $69.0 million in the prior quarter.
• Across five years, Inventory topped out at $69.3 million in Q3 2025 and bottomed at $28.8 million in Q3 2023.
• A 5-year average of $45.0 million and a median of $38.3 million in 2023 frame the typical range for Inventory.
• Annual changes were most pronounced in 2023 — Inventory slipped 22.16% — and 2024, when it surged 59.03%.
• Neurocrine Biosciences' Inventory stood at $35.1 million in 2022, then advanced by 9.12% to $38.3 million in 2023, then soared by 49.87% to $57.4 million in 2024, then gained by 20.21% to $69.0 million in 2025, then dropped by 6.52% to $64.5 million in 2026.
• Business Quant data shows NBIX's Inventory at $64.5 million in Q1 2026, $69.0 million in Q4 2025, and $69.3 million in Q3 2025.